Deferiprone for thalassaemia [10]

Lancet

Volumn 356, Issue 9239, 2000, Pages 1444-1445

  Pippard, Martin J ^a   Weatherall, David J ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

DRUG EFFICACY; DRUG SAFETY; HUMAN; IRON CHELATION; IRON OVERLOAD; LETTER; LIFE EXPECTANCY; LIVER FIBROSIS; PRIORITY JOURNAL; THALASSEMIA; NOTE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; HUMANS; IRON CHELATING AGENTS; PYRIDONES; THALASSEMIA;

EID: 0034699758     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)74089-7     Document Type: Letter

References (5)

1. Deferiprone for thalassaemia
2. Oral iron chelation therapy for thalassaemia; an uncertain scene
3. Iron chelators for thalassaemia
4. Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalassemia major
5. Iron-chelating therapy and the treatment of thalassemia